

Correction to *Lancet Oncol* 2017; 18: 672–81

García-Donas J, Font A, Pérez-Valderrama B, et al. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. *Lancet Oncol* 2017; **18**: 672–81—In this Article, the declaration of interests should read “JG-D reports personal fees from Astellas, Janssen; grants and personal fees from AstraZeneca, Pfizer, Pierre Fabre, Merck, BioClin, Bristol Myers Squibb, Novartis, and MSD; grants, personal fees, and non-financial support from Roche; and grants from GammaMabs, outside the submitted work. AF reports grants from Astellas, AstraZeneca, Pierre-Fabre; personal fees and non-financial support from Sanofi, Janssen, Bayer, and Roche, outside the submitted work. BP-V reports personal fees from Astellas Pharma, Novartis, Pfizer, Pierre Fabre, Bayer, Sanofi, Bristol-Myers Squibb, Ipsen, and Janssen-Cilag, during the conduct of the study. MAC reports personal fees from Pierre Fabre, Janssen, Sanofi, Astellas, and Bayer, during the conduct of the study. JAA reports grants and personal fees from GlaxoSmithKline and Novartis; personal fees and non-financial support from Jansen Cilag; grants, personal fees and non-financial support from BMS; personal fees from Pfizer, Roche, and EUSA; grants from Sanofi and Pierre Fabre, outside the submitted work. NL reports personal fees from Pfizer, Sanofi, Pierre Fabre, Roche, Ipsen, Pharma Mar, BMS, Bayer, AstraZeneca, Astellas, and MSD, outside the submitted work. JCV-G reports personal fees from Pfizer, Astellas, Janssen, MSD, Bayer, Roche, Bristol, AstraZeneca, Boehringer, Pierre Fabre, Novartis, Ipsen, Celgene, Lilly, Merck, Sanofi, and Mundipharma, outside the

submitted work. BM reports personal fees and non-financial support from Pfizer and Janssen; personal fees from Novartis, Astellas Oncology, BMS, Sanofi, Ipsen, Bayer; and grants and personal fees from Roche, outside the submitted work. AGdA reports advisory board, consultancy and speaker honoraria or travel support from Pierre Fabre, Roche, Bristol-Myers Squibb, MSD, Pfizer, Novartis, Bayer, Janssen, Sanofi, Astellas, EUSA Pharma, and Eisai; and research funding from Astellas. DC reports personal fees from Janssen, Roche, Astellas, MSD, Ipsen, Pfizer, BMS, Bayer, AstraZeneca, Novartis, Lilly, Sanofi, Pierre Fabre, and Boehringer, outside the submitted work. EG reports grants from Pierre-Fabre, during the conduct of the study; personal fees and non-financial support from Janssen, Pfizer, Bayer, Ipsen, Novartis, BMS, Rovi; personal fees from Menarini and Leo Pharma; and non-financial support from Pierre-Fabre, outside the submitted work. UA reports non-financial support from Novartis, Pierre Fabre, and Ipsen; personal fees from Bayer, Janssen, Astellas, and Pfizer; and personal fees and non-financial support from Sanofi, Roche, and BMS, outside the submitted work. XGdM reports personal fees from Pfizer, Ipsen, BMS, Roche, Lilly, Pharmamar, EusaPharma, and Pierre Fabre; and grants from AstraZeneca, outside the submitted work. MD has participated in advisory boards, consultancy, and speaker bureaus for Roche, Bristol-Myers Squibb, MSD, Pfizer, Janssen, Sanofi, Astellas; and received travel and accommodations expenses from Roche, Astellas, Janssen, Bayer, and Lilly. JP has received honoraria as a consultant on advisory boards from Pfizer, Astellas, Janssen, MSD, Bayer, Roche, BMS, Boehringer, AstraZeneca, Ipsen, Novartis, EUSA Pharma, Eisai, and Sanofi; and as speaker from Kyowa, Pierre-Fabre, Celgene, Lilly, and Merck. RM-B has served as a consultant or on advisory and/or speakers bureaus for Sanofi Aventis, Bayer, Janssen, AstraZeneca, Merck Sharp & Dohme,

and Asofarma; and received travel and accommodations expenses from Roche, Sanofi Aventis, Astellas, Janssen, Merck Sharp & Dohme, Bayer, Pharmacyclics, Clovis Oncology, and Lilly. JLP-G reports non-financial support from Pierre Fabre, during the conduct of the study; non-financial support from Roche, BMS, and MSD, outside the submitted work. JB reports grants and personal fees from Pfizer, Merck, BMS; personal fees from Genentech, AstraZeneca, Pierre-Fabre; and grants from Takeda, during the conduct of the study. JAV, SH-P, and MdML declare no competing interests.” This correction has been made to the online version as of Jan 3, 2019.

Correction to *Lancet Oncol* 2018; 19: 1493–503

Zackrisson S, Lång K, Rosso A, et al. One-view breast tomosynthesis versus two-view mammography in the Malmö Breast Tomosynthesis Screening Trial (MBTST): a prospective, population-based, diagnostic accuracy study. *Lancet Oncol* 2018; **19**: 1493–503—In this Article, in table 1 and table 4, the age groups should have been listed as follows: 40–49, >49–59, >59–69, and >69. The title and legend of figure 2 should have read as follows: “Number of false-positive results among participants over the trial period who were recalled only on digital breast tomosynthesis and digital mammography, respectively. These numbers do not include women recalled on both modalities”. The key on the graph has also been updated. These corrections have been made to the online version as of Jan 3, 2019.